Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.
Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
A observational or N/A phase clinical study on Patients With High-risk Prostate Cancer, this trial is completed. The trial is conducted by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa and has accumulated 11 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Jul 2020 — Nov 2020 [monthly]
Completed
Status: Unknown Status → Completed
-
Jun 2018 — Jul 2020 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
For direct contact, visit the study record on ClinicalTrials.gov .